Latil et al. carried out an international, randomized, double-blind, parallel-group, tamsulosin-controlled study in 206 men with BPH-associated LUTS and showed that anti-inflammatory treatment by Permixon could reduce MIF expression and the international prostate symptom score (IPSS) in BPH patients (Latil et al., 2015). The gene discussed is MIF; the disease is benign prostatic hyperplasia.